Ornithine aspartate instructions for use. Aspartic acid
Gross formula
C5H12N2O2Pharmacological group of the substance Ornithine
Nosological classification (ICD-10)
CAS code
70-26-8Characteristics of the substance Ornithine
Colorless crystals. Easily soluble in water, alcohol, slightly soluble in ether.
Pharmacology
Pharmacological action- hepatoprotective, detoxifying, hypoazotemic.Has a hypoammonemic effect. Utilizes ammonium groups in the synthesis of urea (ornithine cycle). Reduces the concentration of ammonia in the blood plasma, helps normalize the body's acid-base balance and the production of insulin and growth hormone. Improves protein metabolism in diseases requiring parenteral nutrition.
When ornithine is taken orally, aspartate dissociates into its constituent components (ornithine and aspartate), which are absorbed in the small intestine by active transport through the intestinal epithelium.
It is excreted in urine through the urea cycle.
Application of the substance Ornithine
Hyperammonemia, hepatitis, liver cirrhosis, hepatic encephalopathy (latent and severe), incl. as part of complex therapy for impaired consciousness (precoma or coma); as a corrective additive to preparations for parenteral nutrition in patients with protein deficiency.
Contraindications
Hypersensitivity, severe renal failure (creatinine concentration more than 3 mg/100 ml).
Use during pregnancy and breastfeeding
During pregnancy, it is possible only under the strict supervision of a doctor. Breastfeeding should be stopped during treatment.
Side effects of the substance Ornithine
Skin allergic reactions, nausea, vomiting.
Interaction
Pharmaceutically incompatible with penicillin, vitamin K, rifampicin, meprobamate, diazepam, phenobarbital, ethionamide.
Routes of administration
Inside, intravenously, intramuscularly.
Precautions for the substance Ornithine
Use with caution for vehicle drivers and people whose work requires quick mental and physical reactions and is also associated with increased concentration.
If nausea or vomiting occurs, the rate of administration of the drug should be reduced.
Interactions with other active ingredients
Trade names
| Name | The value of the Vyshkowski Index ® |
Rp: Sol. Ornithini aspartat 5.0 - 10 ml
D.t.d.N. 5 in amp.
S. According to the scheme.
Pharmacological action
Hypoammonemic agent. Reduces elevated levels of ammonia in the body, particularly in liver diseases. The action is associated with participation in the ornithine cycle of Krebs urea formation (the formation of urea from ammonia). Promotes the production of insulin and growth hormone. Improves protein metabolism in diseases requiring parenteral nutrition.
Ornithine aspartate in the body dissociates into the amino acids ornithine and aspartate, which are absorbed in the small intestine by active transport through the intestinal epithelium. Excreted in urine.
Directions for use
For adults: Inside. Dissolve the contents of 1-2 Hepa-Merz packets in a large amount of liquid (in particular a glass of water or juice) and take during or after meals up to 3 times a day.
IV. Often the dosage is up to 4 ampoules (40 ml) per day. In case of precoma or coma, administer up to 8 ampoules (80 ml) over 24 hours, depending on the severity of the condition. Before administration, add the contents of the ampoule to 500 ml of solution, but do not dissolve more than 6 ampoules in 500 ml of infusion solution.
The highest rate of administration of L-ornithine-L-aspartate is 5 g/h (which corresponds to the contents of 1 ampoule).
The period of treatment with Hepa-Merz is determined by the doctor depending on the clinical condition of the patient.
Indications
Treatment of patients with concomitant diseases and complications caused by impaired detoxification function of the liver (in particular with cirrhosis of the liver) with symptoms of latent or severe hepatic encephalopathy
- especially disturbances of consciousness (precoma, coma).
Contraindications
Acute and chronic liver diseases accompanied by hyperammonemia. Hepatic encephalopathy.
- For dynamic study of the function of the pituitary gland.
- As a corrective additive to drugs for parenteral nutrition in patients with protein deficiency.
- Severe renal dysfunction (serum creatinine content more than 3 mg/100 ml).
- If nausea or vomiting occurs, the rate of administration should be optimized.
- When using a specific dosage form of ornithine, compliance with the specific indications must be observed.
- Impact on the ability to drive vehicles and operate machinery
- Ornithine can cause disturbances in concentration and speed of psychomotor reactions.
Side effects
From the gastrointestinal tract: rarely (>1/10,000,<1/1000) — тошнота, рвота, боль в желудке, метеоризм, диарея.
- From the musculoskeletal system: very rarely (<1/10 000) — боль в суставах.
- These adverse reactions are often short-lived and do not require discontinuation of the medication. They disappear when the dosage or rate of administration of the drug is reduced.
- Allergic reactions are possible.
Release form
Gran. 3 g/5 g package 5 g, No. 30, No. 50, No. 100
Ornithine aspartate 3 g/5 g.
Other ingredients: anhydrous citric acid, sodium saccharin, sodium cyclamate, povidone 25, fructose, lemon flavor, orange flavor, yellow-orange dye S (E110).
Conc. d/r-ra d/inf. 5 g amp. 10 ml, no. 10
Ornithine aspartate 0.5 g/ml.
Other ingredients: water for injection.
ATTENTION!
The information on the page you are viewing is created for informational purposes only and does not in any way promote self-medication. The resource is intended to provide healthcare workers with additional information about certain medications, thereby increasing their level of professionalism. Use of the drug " Ornithine aspartate“mandatorily requires consultation with a specialist, as well as his recommendations on the method of use and dosage of the medicine you have chosen.
2,5-diaminopentanoic acid
Chemical properties
Ornithine – diaminovaleric acid . Structural formula of the chemical compound: NH2CH2CH2CH2CH(NH2)COOH. In peptide sequences the substance is designated Orn. The drug is present in free form in living organisms and is a component of some.
If carbon monoxide 4 is split off from a molecule of diaminovaleric acid (the reaction occurs during the process of decay of a corpse), then putrescine - one of the main components of cadaveric poison. L-ornithine (L-ornithine) is an optical isomer of this substance. It was first synthesized from shark liver tissue in 1937. The amino acid is colorless crystals that are easily soluble in water and alcohol, and sparingly soluble in ether. Molecular mass of chemical compound = 132.2 grams per mole. About 50 tons of this lek are produced annually in the world. means.
In the composition of various drugs, the substance is most often found in the form ketoglutarate or aspartate .
Pharmacological action
Hepatoprotective , detoxification , hypoazotemic .
Pharmacodynamics and pharmacokinetics
Ornithine takes part in synthesis processes urea (V ornithine cycle ), promotes the utilization of ammonium groups, reduces the concentration ammonia in the blood. Thanks to this drug, the body's acid-base balance is normalized and growth hormone is produced.
If you use the medicine for diseases that require parenteral nutrition, it significantly improves protein metabolism.
After taking the drug orally ornithine aspartate dissociates into aspartate And ornithine , which are quickly and completely absorbed in the small intestine using active transport reactions through epithelial tissues. The medicine is excreted through the kidneys with urine during the urea cycle.
Indications for use
The drug is prescribed:
- at hyperammonemia ;
- patients with or;
- with latent or pronounced hepatic encephalopathy ;
- as part of complex treatment of disorders of consciousness ( precoms i) due to hepatic encephalopathy ;
- as an additive to parenteral nutrition for patients with protein deficiency;
- for diagnostics, dynamic study of work.
Contraindications
L-ornithine contraindicated for use:
- when on this substance;
- patients with severe renal failure ( creatinine more than 3 mg per 100 ml).
Side effects
Ornithine is well tolerated. Rarely, allergic skin rashes, vomiting, nausea may occur. If allergies occur, it is recommended to consult a doctor.
Ornithine, instructions for use (Method and dosage)
The drug is prescribed intravenously, orally or intramuscularly.
Intravenous medication is prescribed as infusions. The dosage regimen, frequency and duration of infusion depend on various parameters and are determined by the attending physician individually. Typically 20 grams of the substance are dissolved in 500 ml infusion solution . The maximum speed at which the medicine can be administered is 5 grams per hour. The maximum daily dosage is 40 g.
Overdose
There is no information about an overdose of the drug.
Interaction
Ornithine is not pharmaceutically compatible with benzylpenicillin benzathine , , , And ethionamide .
The medicine should not be mixed in the same syringe with and benzathine benzylpenicillin .
Terms of sale
No recipe needed.
Special instructions
If vomiting or nausea occurs during intravenous administration of the drug, it is recommended to reduce the infusion rate.
It is necessary to strictly observe the compliance of the specific dosage form of the drug with the indications for use.
During pregnancy and lactation
Only the attending physician can prescribe medicine to pregnant women according to direct indications. It is recommended to stop breastfeeding, as the drug is excreted in milk.
Drugs containing (Analogs)
Level 4 ATX code matches:Structural analogues of this substance: , Ornilatex , Larnamine , Ornitsetil . Also lek. the product is included in: solution for infusion Aminoplasmal Hepa , Aminoplasmal E , .
0
A clinical multicenter comparative study examined the effectiveness and safety of L-ornithine-L-aspartate (Hepa-Merz), which belongs to the group of hepatoprotective agents that affect metabolic disorders. The study included 232 patients with acute pancreatitis. It has been established that L-ornithine-L-aspartate (Hepa-Merz) reduces the severity of neurological disorders in pancreatic necrosis. The drug has pronounced hepatoprotective properties.
According to the literature and our observations, the incidence of acute pancreatitis is steadily increasing; in frequency it ranks third after acute appendicitis and cholecystitis. Treatment of acute pancreatitis, especially its destructive forms, is still a difficult surgical problem due to its high mortality rate - from 25 to 80%.
The liver is the first target organ that bears the brunt of pancreatogenic toxemia in the form of a massive entry into the blood flowing through the portal vein of activated pancreatic and lysosomal enzymes, biologically active substances, toxic products of the breakdown of pancreatic parenchyma during necrobiosis and activation of the kallikrein-kinin system.
As a result of the action of damaging factors, deep microcirculatory disorders develop in the liver parenchyma; activation of mitochondrial cell death factors and induction of apoptosis of liver cells occurs in hepatocytes. Decompensation of internal detoxification mechanisms aggravates the course of acute pancreatitis due to the accumulation in the body of many toxic substances and metabolites that concentrate in the blood and create a secondary hepatotropic effect.
Liver failure is one of the most serious complications of acute pancreatitis. It often determines the course of the disease and its outcome. It is known from the literature that in 20.6% of patients with edematous pancreatitis and in 78.7% with a destructive process in the pancreas, various liver functions are impaired, which significantly worsens the results of treatment and in 72% of cases is the direct cause of death.
In view of this, the need for adequate prevention and treatment of liver failure in every patient with acute pancreatitis using the entire range of conservative measures is obvious. Today, one of the priority areas of complex therapy for liver failure in acute pancreatitis is the inclusion of hepatoprotectors in the treatment, in particular L-ornithine-L-aspartate (Hepa-Merz).
The drug has been on the pharmaceutical market for several years, it has proven itself and is successfully used in therapeutic, neurological, and toxicological practice for acute and chronic liver diseases. The drug stimulates the detoxification function of the liver, regulates metabolism in hepatocytes, and has a pronounced antioxidant effect.
From November 2009 to March 2010, a multicenter non-randomized clinical study was conducted to study the effectiveness of the hepatoprotector L-ornithine-L-aspartate (Hepa-Merz) in the complex treatment of patients with acute pancreatitis. The study included 232 patients (150 (64.7%) men and 82 (35.3%) women) with acute pancreatitis confirmed by clinical, laboratory and instrumental methods. The age of the patients ranged from 17 to 86 years, with an average of 46.7 (34; 58) years. 156 (67.2%) patients were diagnosed with an edematous form of pancreatitis, 76 (32.8%) - destructive forms: 21 (9.1%) - hemorrhagic pancreatic necrosis, 13 (5.6%) - fatty, 41 (17.7%) - mixed, 1 (0.4%) - post-traumatic.
All patients received basic complex conservative therapy (blockade of exocrine pancreatic function, infusion-detoxification, antibacterial agents).
L-ornithine-L-aspartate (Hepa-Merz) was used in a complex of therapeutic measures in 182 (78.4%) patients (main group); 50 (21.6%) patients made up the control group, in which this drug was not used. The drug was prescribed from the 1st day of inclusion of the patient in the study according to the developed scheme: 10 g (2 ampoules) intravenously at an administration rate of no more than 5 g/h per 400 ml of physiological sodium chloride solution for 5 days, from the 6th day - orally (the drug in the form of granules, 1 packet, 3 g, 3 times a day for 10 days).
The severity of the patients' condition was assessed using the SAPS II physiological state severity scale. Depending on the total SAPS II score, 2 subgroups of patients were identified in both groups: with a total score<30 и >30.
Subgroup with severity of condition according to SAPS II<30 баллов составили 112 (48,3%) пациентов, в том числе 97 (87%) - из основной группы: мужчин - 74 (76,3%), женщин - 23 (23,7%), средний возраст - 40,9 (33; 45) года, тяжесть состояния - 20,4±5,2 балла; из контрольной группы было 15 (13%) пациентов: мужчин - 11 (73,3%), женщин - 4 (26,7%), средний возраст - 43,3 (28,5; 53) года, тяжесть состояния - 25±6 баллов.
The subgroup with a total SAPS II score >30 consisted of 120 (51.7%) patients, including 85 (71%) from the main group: men - 56 (65.9%), women - 29 (34.1%) ), average age - 58.2 (45; 66.7) years, severity of condition - 36.3+5.6 points; from the control group there were 35 (29%) patients: men - 17 (48.5%), women - 18 (51.4%), average age - 55.4 (51; 63.5) years, severity of condition - 39 .3±5.9 points.
The study identified 4 base points: 1st, 3rd, 5th and 15th days. To assess the effectiveness of treatment, the severity of the patients' condition was determined over time using the SOFA Integral Scale; laboratory parameters were examined: bilirubin concentration, protein levels, urea and creatinine, cytolysis enzymes - alanine aminotransferase (ALT), aspartate aminotransferase (AST). The degree of impairment of cognitive functions and the rate of their recovery during treatment were assessed using the Number Link Test (NTT).
Mathematical processing of the factual material was carried out using basic methods of biomedical statistics using the Microsoft Office Excel 2003 and BIOSTAT application package. When describing group characteristics, we calculated the standard deviation of the mean value of the characteristic with its parametric distribution and the interquartile interval with a nonparametric distribution. The significance of the differences between the 2 parameters was assessed using the Mann-Withney and x2 tests. Differences were considered statistically significant at p=0.05.
In patients of the main group with severity of condition according to SAPS II<30 баллов применение L-орнитин-L-аспартата (Гепа-Мерц) в комплексе лечения привело к более быстрому восстановлению нервно-психической сферы, что оценивалось в ТСЧ. При поступлении у пациентов обеих групп длительность счета была выше нормы (норма - не более 40 с) на 57,4% в основной группе и на 55,1% - в контрольной: соответственно 94 с (80; 98) и 89,5 с (58,5; 116). На фоне терапии отмечалась положительная динамика в обеих группах. На 3-й сутки длительность счета составила 74 с (68; 78) в основной группе и 82,3 с (52,5; 100,5) - в группе сравнения, что превышало норму на 45,9 и 51,2% соответственно (р=0,457, Mann-Withney). На 5-е сутки время в ТСТ составило 50 с (48; 54) в основной группе и 72,9 с (44; 92) - в контрольной, что превышало норму на 20 и 45,2% соответственно (р=0,256, Mann-Withney). Статистически достоверные изменения отмечены на 15-е сутки исследования: в основной группе - 41 с (35; 49), что превышало нормальное значение на 2,4%, а в контрольной — 61 с (41; 76) (больше нормы на 34,4%; р=0,038, Mann-Withney) - рисунок "Динамика состояния нервно-психической сферы у больных с суммарным баллом по SAPS II <30".
In patients with a severity of condition according to SAPS II >30 points, the study revealed a positive effect of L-ornithine-L-aspartate (Hepa-Merz) on the dynamics of biochemical parameters; the most significant changes concerned the indicators of cytolytic syndrome (ALT, AST) and the rate of recovery of neuropsychic functions.
During dynamic monitoring of the severity of the condition of the patients, assessed by the SOFA scale, a faster normalization was also noted in the main group (Figure "Dynamics of the severity of the condition in patients with a total score on SAPS II >30"). The severity of the condition of patients in the main and control groups on the 1st day of the study on the SOFA scale was 4 (3; 6.7) and 4.2 (2; 7) points, respectively, on the 3rd day of the study - 2 (1; 3), respectively .7) and 2.9 (1; 4) points (p=0.456, Mann-Withney), on the 5th day - 1 (0; 2) and 1.4 (0; 2) points (p=0.179), respectively , Mann-Withney), on the 15th day: in the main group on average 0 (0; 1) points, in 13 (11%) patients - 1 point; in the control group, signs of organ dysfunction were observed in 12 (34%) patients; the average SOFA value in this group was 0.9 (0; 2) points (p = 0.028, Mann-Withney).
The use of L-ornithine-L-aspartate (Hepa-Merz) in our study was accompanied by a more pronounced decrease in cytolysis parameters than in the control (figures “Dynamics of ALT content in patients with a total SAPS II score >30” and “Dynamics of AST content in patients with a total SAPS II score >30").
On day 1, ALT and AST levels exceeded the upper limit of normal in all patients. The average ALT content in the main group was 137 U/l (27.5; 173.5), in the control group - 134.2 U/l (27.5; 173.5), AST - 120.5 U/l, respectively ( 22.8; 99) and 97.9 U/l (22.8; 99). On the 3rd day, the ALT content was, respectively, 83 U/l (25; 153.5) and 126.6 U/l (25; 153.5) (p-0.021, Mann-Withney), AST - 81.5 U /l (37; 127) and 104.4 U/l (37; 127) (p=0.014, Mann-Withney). On the 5th day, the average ALT content in the main and control groups was 62 U/l (22.5; 103) and 79.7 U/l (22.5; 103) respectively (p=0.079, Mann-Withney), a AST - 58 U/l (38.8; 80.3) and 71.6 U/l (38.8; 80.3) (p=0.068, Mann-Withney). The concentration of ALT and AST in patients receiving L-ornithine-L-aspartate (Hepa-Merz) reached normal values on the 15th day. The ALT level in the main group was 38 U/l (22.5; 49), in the comparison group - 62 U/l (22.5; 49) (p = 0.007, Mann-Withney), the AST level was 31.5, respectively U/l (25; 54) and 54.2 U/l (25; 70) (p=0.004, Mann-Withney).
The study of attention using TSC in patients with a severity of condition according to SAPS II >30 points also revealed better results in the main group (Figure "Dynamics of the state of the neuropsychic sphere in patients with a total score according to SAPS II >30").
Their counting speed by the 3rd day was higher than in the comparison group by 18.8%: it took 89 s (69.3; 105) and 109.6 s (90; 137), respectively (p = 0.163, Mann -Withney); by day 5 the difference reached 34.7%: 59 s (52; 80) and 90.3 s (66.5; 118), respectively (p = 0.054, Mann-Withney). On the 15th day in the main group, counting took an average of 49 s (41.5; 57), which was 47.1% more than the same indicator in the control group: 92.6 s (60; 120); p=0.002, Mann-Withney.
The immediate results of treatment should also include a reduction in hospitalization time by an average of 18.5% in patients of the main group (p = 0.049, Mann-Withney).
In the control group there were 2 (6%) deaths from increasing multiple organ failure (p = 0.15; Χ 2), in the main group there were no deaths.
The observation showed that in the vast majority of cases, L-ornithine-L-aspartate (Hepa-Merz) was well tolerated by patients. In 7 (3.8%) patients, side effects were noted, in 2 (1.1%) the drug was discontinued due to the development of an allergic reaction, in 5 (2.7%) dyspeptic symptoms were noted in the form of nausea, vomiting, which were stopped when reducing the rate of drug administration.
Timely use of L-ornithine-L-aspartate (Hepa-Merz) in a complex of therapeutic measures for acute pancreatitis is pathogenetically justified and can significantly reduce the severity of endogenous intoxication. L-ornithine-L-aspartate (Hepa-Merz) is well tolerated by patients.
Literature
1. Bueverov A.O. Hepatic encephalopathy as the main manifestation of liver failure // Materials of the Merz satellite symposium “Liver diseases and hepatic encephalopathy”, April 18, 2004, Moscow. - P. 8.
2. Ivanov Yu.V. Modern aspects of the occurrence of functional liver failure in acute pancreatitis // Mathematical morphology: electronic mathematical and medical-biological journal. -1999; 3 (2): 185-195.
3. Ivashkin V.T., Nadinskaya M.Yu., Bueverov A.O. Hepatic encephalopathy and methods of its metabolic correction // Breast Cancer Library. - 2001; 3 (1): 25-27.
4. Laptev V.V., Nesterenko Yu.A., Mikhailusov S.V. Diagnosis and treatment of destructive pancreatitis - M.: Binom, 2004. - 304 p.
5. Nadinskaya M.Yu., Podymova S.D. Treatment of hepatic encephalopathy with Hepa-Merz // Materials of the satellite symposium of the Merz company “Liver diseases and hepatic encephalopathy”, April 18, 2004, Moscow. - P. 12.
6. Ostapenko Yu.N., Evdokimov E.A., Boyko A.N. Experience of conducting a multicenter study in medical institutions in Moscow to study the effectiveness of using Hepa-Merz for endotoxicosis of various etiologies // Materials of the second scientific and practical conference, June 2004, Moscow. - P. 31-32.
7. Popov T.V., Glushko A.V., Yakovleva I.I. and others. Experience of using the drug Selenase in the complex of intensive care of patients with destructive pancreatitis // Consilium Medicum, Infections in surgery. - 2008; 6 (1): 54-56.
8. Savelyev V.S., Filimonov M.I., Gelfand B.R. and others. Acute pancreatitis as a problem of urgent surgery and intensive care // Consilium Medicum. - 2000; 2 (9): 367-373.
9. Spiridonova E.A., Ulyanova Ya.S., Sokolov Yu.V. The use of Hepa-Merz drugs in the complex therapy of fulminant viral hepatitis // Materials of the satellite symposium of the Merz company “Liver diseases and hepatic encephalopathy”, April 18, 2004, Moscow. - P. 19.
10. Kircheis G. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrosis and hepatic encephalopathy: results of placebo-controlled, double-blind study // Hepatology. - 1997; 1351-1360.
11. Nekam K. et al. Effect of in vivo treatment with ornitine-aspartate hepamerz on the activity and expression of superoxide dismutase SOD in patients with cirrhosis of the liver// Hepatology. -1991; 11: 75-81.
Liked a medical article, news, lecture on medicine from the category
« / / / »:
is a related amino acid to arginine. Combining them into one group is caused by a similar effect on the body. L ornithine, isolated from shark liver in 1937 by D. Akkarman, like arginine, stimulates the synthesis of growth hormone - somatotropin. As a non-essential amino acid, ornithine is not included in proteins, but its popularity among bodybuilding athletes is due to the fact that it promotes rapid muscle gain.
There are two subgroups of ornithine: L and D. Group D has no value for bodybuilders. In sports nutrition, only group L amino acids are used. A small amount of arginine is found in connective tissue and in human blood plasma. Ornithine is also isolated from plant products.
Ornithine is a related amino acid to arginine.
Properties and Functions
The amino acid is used not only in sports nutrition, but also in medicine. Medicinal preparations with the addition of a biologically active component are typical in the treatment of the following diseases:
- hepatitis;
- renal failure;
- cirrhosis;
- protein deficiency;
- excess urea content in the blood.
Ornithine, as a hepatoprotector, is a powerful protector of the body. The use of amino acids has a positive effect on the regeneration and restoration of liver cells. At the same time, ornithine protects the body from the negative effects of toxic substances, which is important for people with liver disorders. Scientific studies indicate acceleration of blood movement through blood vessels under the influence of non-essential amino acids.
The amino acid is used in the treatment of hepatitis
The additive is also used in burn therapy. The amino acid has a positive effect on tissue regeneration. An advantage of its use will be an increase in overall skin tone.
The amino acid supplement promotes the synthesis of niacin (nicotinic acid) in the body.
The benefit of niacin is to speed up metabolism, which has a positive effect on the rate of weight loss.
Niacin deficiency manifests itself in loss of appetite, muscle weakness, roughening and flaking of the skin. Taking ornithine helps to accumulate the required amount of nicotinic acid in the body and, in synergy with it, overcome the noted problems.
L ornithine is involved in the removal of ammonia from the body. Under the influence of amino acids, ammonia, as a protein breakdown product, is converted into urea and excreted from the body. Exceeding the permissible level of ammonia in the blood is dangerous for human life, as it can cause endotoxicosis. The processing of ammonia into urea and its subsequent removal blocks the development of negative processes under the influence of toxic substances. This process also has a beneficial effect on reducing the general excitability of a person.
L ornithine is involved in the removal of ammonia from the body
The detoxifying properties of amino acids are used in complex therapy of malignant tumors.
ABOUT rnitine has a number of other properties:
- strengthening the immune system and, as a result, increasing the body’s resistance to diseases;
- strengthening connective tissues;
- energy generation in the process of fat breakdown;
- muscle recovery;
- maintaining the acid-base balance of the body.
An amino acid related to arginine is of great importance in the treatment of diseases of the gastrointestinal tract, alcohol dependence, schizophrenia and Down syndrome. As a sedative, the amino acid is introduced into the diet of aggressive people with hyperactivity syndrome.
Arginine-related amino acid is of great importance in the treatment of gastrointestinal diseases
You can buy L ornithine on the American website, where there are always promotions, and using our link you are guaranteed to receive an additional 5% discount. It also works. Therefore, if you have already decided which L ornithine is best for you, then it can be found on.
The importance of amino acids for athletes
A feature of sports is the increased consumption of protein foods, which leads to an overload of the body with waste products. Although ornithine is synthesized in the body and converted into arginine, its amount is not enough to achieve significant results in bodybuilding and reduce the load on the liver. Therefore, additional intake of the amino acid as a hepatoprotector is indicated for bodybuilders and powerlifters. This is due to the positive effect of ornithine on the overall effectiveness of training and health.
First, ornithine stimulates the production of growth hormone, which accumulates in the pituitary gland. Growth hormone promotes rapid fat burning and accumulation of muscle mass, which helps you lose weight and gain an athletic figure. The hormone also has the properties of normalizing glucose levels.
For greater effect, take ornithine before bed, and the peak secretion of the hormone occurs at 90 minutes of night rest.
For greater effect, take ornithine before bed, and the peak secretion of the hormone occurs at 90 minutes of night rest.
It is worth noting that taking an amino acid stimulates the mobilization of fat not in response to sleep, but in response to a set of measures: proper nutrition, strength training, and adequate sleep.
Insulin synthesis is the second most important property of an amino acid supplement for an athlete. Increased insulin secretion is necessary in bodybuilding when bodybuilders work on mass.
Ornithine cannot be replaced when drying the body. The breakdown of fats occurs under the influence of growth hormone both during the day and at night. At the same time, the athlete does not feel exhausted, since ornithine increases the body’s energy. In addition, the amino acid supplement reduces pain sensitivity.
The importance of amino acids for strengthening and restoring ligaments and tendons is important.
The importance of amino acids for strengthening and restoring ligaments and tendons
The amino acid that synthesizes growth hormone is found in plant foods. There is no ornithine in animal products. However, it can be synthesized from arginine, which is found in protein foods. These include nuts, pumpkin seeds, meat, fish and eggs. Therefore, obtaining l ornithine from food is insignificant and does not cover the required daily dose of a bodybuilder, which explains the need for dietary supplements.
Admission rules
Depending on the goals pursued, it is recommended to take 5 g of ornithine three times a day. It is best to take it in the morning on an empty stomach, and subsequent doses should be taken after meals. Take the sports supplement with juice or water and never milk. To increase the secretion of growth hormone, the third dose is taken immediately before bedtime.
L ornithine is found in walnuts
For intramuscular consumption, the daily dose of ornithine ranges from 4 to 14 g, divided into 2 administrations. Intravenously, 4 g of the active substance is administered once a day.
To increase the rate of fat burning, ornithine supplementation is supplemented with amino acids such as carnitine and arginine. In synergy with niacinamide, calcium, vitamin B6, vitamin C and potassium, the rate of growth hormone synthesis increases.
Contraindications and side effects
Taking ornithine is contraindicated for pregnant and lactating women.
It is unacceptable to use a dietary supplement as a sports nutrition for people suffering from schizophrenia and renal failure if the maximum permissible creatinine norm (3 mg/100 ml) is exceeded.
Amino acid supplementation may cause nausea, diarrhea, and vomiting.
The drug reduces the speed of motor reactions. As a sedative, ornithine leads to a general decrease in concentration.
In rare cases, jet injection of an amino acid leads to shortness of breath and pain in the sternum.
